

Hartmut Derendorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9103850/publications.pdf>

Version: 2024-02-01

398
papers

17,677
citations

16791

66
h-index

25983

112
g-index

415
all docs

415
docs citations

415
times ranked

17216
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma α -indospicine and 3-nitropropionic acid in ponies fed creeping indigo: Comparison with results from an episode of presumptive creeping indigo toxicosis. <i>Equine Veterinary Journal</i> , 2022, 54, 145-152.	0.9	2
2	Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight. , 2022, , 135-164.		0
3	Tobacco smoke exposure enhances reward sensitivity in male and female rats. <i>Psychopharmacology</i> , 2021, 238, 845-855.	1.5	5
4	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891.	2.3	41
5	Pharmacokinetics and Determination of Tumor Interstitial Distribution of a Therapeutic Monoclonal Antibody Using Large-Pore Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 3061-3068.	1.6	4
6	Microdialysis sampling to monitor target-site vancomycin concentrations in septic infants: a feasible way to close the knowledge gap. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106405.	1.1	6
7	Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 106007.	1.1	37
8	Evaluation of the Effects of <i>Maytenus ilicifolia</i> on the Activities of Cytochrome P450 3A and P-glycoprotein. <i>Current Drug Metabolism</i> , 2020, 21, 281-290.	0.7	6
9	Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics. <i>GMS Infectious Diseases</i> , 2020, 8, Doc17.	0.5	4
10	PK/PD Approaches. , 2020, , 1047-1069.		0
11	Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model. <i>Investigational New Drugs</i> , 2019, 37, 364-374.	1.2	24
12	Pharmacokinetics of Oxytetracycline in the Giant Danio (<i>Devario aequipinnatus</i>) following bath immersion. <i>Aquaculture</i> , 2019, 498, 12-16.	1.7	11
13	Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime+Avibactam Combination: A Model-Informed Strategy for its Clinical Development. <i>Clinical Pharmacokinetics</i> , 2019, 58, 545-564.	1.6	30
14	Medications in Space: In Search of a Pharmacologist's Guide to the Galaxy. <i>Pharmaceutical Research</i> , 2019, 36, 148.	1.7	33
15	Determination of Dermal Pharmacokinetics by Microdialysis Sampling in Rats. <i>Current Protocols in Pharmacology</i> , 2019, 85, e58.	4.0	3
16	PK/PD Approaches. , 2019, , 1-23.		2
17	Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1286.e1-1286.e7.	2.8	96
18	Development and Validation of a Sensitive UPLC-MS/MS Method for Quantification of Quercitrin in Plasma: Application to a Tissue Distribution Study. <i>ACS Omega</i> , 2019, 4, 3527-3533.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Drug-Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1289-1291.	2.3	2
20	Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults. <i>Clinical Pharmacokinetics</i> , 2019, 58, 927-941.	1.6	18
21	Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 240-254.	1.5	13
22	Gastric-acid-mediated drug-drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies. <i>Drug Discovery Today</i> , 2019, 24, 845-857.	3.2	8
23	Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight. , 2019, , 1-30.		0
24	Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 275-283.	1.1	21
25	A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against <i>Pseudomonas aeruginosa</i> . <i>Clinical Microbiology and Infection</i> , 2019, 25, 904.e9-904.e16.	2.8	14
26	Dose Optimization Based on Pharmacokinetic-Pharmacodynamic Modeling. , 2019, , 79-120.		9
27	Basic Principles of Biopharmaceutics and Pharmacokinetics During Spaceflight. , 2019, , 1-30.		0
28	Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 704-716.	1.0	10
29	Nonlinear Protein Binding: Not What You Think. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1754-1760.	1.6	20
30	A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1295-1304.	1.3	24
31	A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702166.	3.1	10
32	Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 477-483.	1.3	17
33	Enhanced in vitro activity of tigecycline in the presence of chelating agents. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 799-802.	1.1	3
34	Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1948-1956.	1.6	18
35	Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 190-196.	1.1	14
36	Experimental design and modelling approach to evaluate efficacy of β -lactam/ β -lactamase inhibitor combinations. <i>Clinical Microbiology and Infection</i> , 2018, 24, 707-715.	2.8	16

#	ARTICLE	IF	CITATIONS
37	PK/PD Approaches. , 2018, , 1-23.		2
38	Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 119-125.	1.4	23
39	Quantitative determination of armodafinil in human plasma by liquid chromatography-electrospray mass spectrometry: Application to a clinical study. Biomedical Chromatography, 2018, 32, e4342.	0.8	4
40	Simultaneous Retrodialysis by Calibrator for Rapid In Vivo Recovery Determination in Target Site Microdialysis. Journal of Pharmaceutical Sciences, 2018, 107, 2259-2265.	1.6	5
41	Prediction of <i>in vivo</i> and <i>in vitro</i> infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 197-207.	1.3	24
42	Potential of ceftazidime by avibactam against β -lactam-resistant <i>Pseudomonas aeruginosa</i> in an <i>in vitro</i> infection model. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw535.	1.3	18
43	A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. International Journal of Antimicrobial Agents, 2017, 49, 449-455.	1.1	17
44	Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	48
45	Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis. Journal of Pharmaceutical Sciences, 2017, 106, 2853-2859.	1.6	36
46	Drugs in space: Pharmacokinetics and pharmacodynamics in astronauts. European Journal of Pharmaceutical Sciences, 2017, 109, S2-S8.	1.9	69
47	Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization. AAPS Journal, 2017, 19, 334-342.	2.2	10
48	Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids. Journal of Pharmaceutical Sciences, 2016, 105, 2509-2514.	1.6	14
49	<i>In vitro</i> pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. Journal of Antimicrobial Chemotherapy, 2016, 71, 1866-1880.	1.3	35
50	Role of Divalent Metal Ions in Atypical Nonlinear Plasma Protein Binding Behavior of Tigecycline. Journal of Pharmaceutical Sciences, 2016, 105, 3409-3414.	1.6	11
51	Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. Expert Review of Anti-Infective Therapy, 2016, 14, 997-1006.	2.0	8
52	Methodologies for Protein Binding Determination in Anti-infective Agents. Methods in Pharmacology and Toxicology, 2016, , 109-125.	0.1	0
53	Microdialysis of Large Molecules. Journal of Pharmaceutical Sciences, 2016, 105, 3233-3242.	1.6	32
54	Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 93-114.	1.5	46

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development. , 2016, , 185-217.		7
56	Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2016, 71, 1012-1021.	1.3	21
57	Quantitation of the impact of <i>CYP3A5</i> A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Clinical Pharmacology in Drug Development, 2015, 4, 387-394.	0.8	8
58	Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. International Journal of Antimicrobial Agents, 2015, 45, 413-419.	1.1	11
59	Development and validation of a HPLC-MS/MS method for the determination of phytolaccagenin in rat plasma and application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 82-88.	1.4	14
60	Concentration-response studies and modelling of the pharmacodynamics of linezolid: Staphylococcus aureus versus Enterococcus faecium. International Journal of Antimicrobial Agents, 2015, 45, 54-60.	1.1	11
61	Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model. International Journal of Antimicrobial Agents, 2015, 45, 151-160.	1.1	21
62	Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy. Advanced Drug Delivery Reviews, 2015, 85, 57-64.	6.6	20
63	Pharmacokinetic Evaluation of Avicularin Using a Model-Based Development Approach. Planta Medica, 2015, 81, 373-381.	0.7	8
64	Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 3149-3155.	1.4	32
65	Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model. Planta Medica, 2015, 81, 1121-1127.	0.7	8
66	Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea. Journal of Clinical Pharmacology, 2015, 55, 1313-1331.	1.0	35
67	Largazole Pharmacokinetics in Rats by LC-MS/MS. Marine Drugs, 2014, 12, 1623-1640.	2.2	15
68	Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. Antimicrobial Agents and Chemotherapy, 2014, 58, 1084-1091.	1.4	9
69	Protein Binding of Rifapentine and Its 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 4904-4910.	1.4	19
70	Determination of Atypical Nonlinear Plasma-Protein-Binding Behavior of Tigecycline Using an In Vitro Microdialysis Technique. Journal of Pharmaceutical Sciences, 2014, 103, 1013-1019.	1.6	27
71	Predicting Pediatric Age-Matched Weight and Body Mass Index. AAPS Journal, 2014, 16, 1372-1379.	2.2	15
72	Measuring drug distribution in the critically ill patient. Advanced Drug Delivery Reviews, 2014, 77, 22-26.	6.6	13

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of <i>para</i> -Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6242-6250.	1.4	31
74	Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. <i>Therapeutic Advances in Infectious Disease</i> , 2014, 2, 17-42.	1.1	21
75	Population Pharmacokinetic Modeling of the Unbound Levofloxacin Concentrations in Rat Plasma and Prostate Tissue Measured by Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 678-686.	1.4	20
76	Pharmacodynamic In Vitro Models to Determine the Effect of Antibiotics. , 2014, , 81-112.		8
77	Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 1-64.	0.2	8
78	Principles of Applied Pharmacokineticâ€“Pharmacodynamic Modeling. , 2014, , 63-79.		10
79	Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against methicillin-resistant <i>Staphylococcus aureus</i> using minimum inhibitory concentration and timeâ€“kill curve based approaches. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 60-67.	1.1	19
80	Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions. <i>Clinical Pharmacokinetics</i> , 2014, 53, 205-212.	1.6	49
81	Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 327-333.	1.1	7
82	Pharmacometrics in Bacterial Infections. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 229-258.	0.2	13
83	Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. <i>Drugs of Today</i> , 2014, 50, 15.	0.7	15
84	Comparison of skin permeability for three diclofenac topical formulations: an in vitro study. <i>Die Pharmazie</i> , 2014, 69, 27-31.	0.3	13
85	When is Protein Binding Important?*. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3458-3467.	1.6	64
86	Pharmacokinetics of Modifiedâ€“Release Prednisone Tablets in Healthy Subjects and Patients With Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 326-333.	1.0	24
87	Microdialysis in Antibiotic Research. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 103-126.	0.2	1
88	Grapefruitâ€“medication interactions. <i>Cmaj</i> , 2013, 185, 507.1-507.	0.9	4
89	Sex related differences on valproic acid pharmacokinetics after oral single dose. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 479-486.	0.8	49
90	Influence of <i>CYP3A5</i> 6986Aâ€“G and <i>ABCB1</i> 3435Câ€“T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 67-78.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and pharmacodynamics of ponesimod, a selective <scp>S1P₁</scp> receptor modulator, in the first human study. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 888-896.	1.1	92
92	Electroencephalogram effects of armodafinil: Comparison with behavioral alertness. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1058-1071.	1.0	4
93	Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents. <i>Clinical Microbiology Reviews</i> , 2013, 26, 274-288.	5.7	121
94	Population Pharmacokinetics of Methotrexate in Egyptian Children with Lymphoblastic Leukemia. <i>Pharmacology & Pharmacy</i> , 2013, 04, 139-145.	0.2	7
95	Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 51-54.	1.1	53
96	Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 352-355.	0.7	11
97	Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29, a novel aqueous nasal spray. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 125-133.	1.1	30
98	Electroencephalogram-based pharmacodynamic measures: a review. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 162-184.	0.3	25
99	PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 239-245.	1.4	76
100	Protein Binding: Do We Ever Learn?. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3067-3074.	1.4	212
101	Absolute/Relative Bioavailability and Metabolism of Dodeca-2<i>E</i>,4<i>E</i>,8<i>Z</i>,10<i>E</i>/<i>Z</i>-Tetraenoic Acid Isobutylamides (Tetraenes) after Intravenous and Oral Single Doses to Rats. <i>Planta Medica</i> , 2011, 77, 1794-1799.	0.7	8
102	Population Pharmacokinetic Model of Human Insulin Following Different Routes of Administration. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1015-1024.	1.0	28
103	Suppression of ciprofloxacin-induced resistant <i>Pseudomonas aeruginosa</i> in a dynamic kill curve system. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 519-524.	1.1	1
104	Clinical Pharmacokinetics of Meropenem and Biapenem in Bile and Dosing Considerations for Biliary Tract Infections Based on Site-Specific Pharmacodynamic Target Attainment. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5609-5615.	1.4	19
105	Erythrocyte binding of cephalosporins. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 129-131.	1.2	10
106	Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 434-441.	1.1	34
107	Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 130-135.	0.6	11
108	Repeated pre-exposure to tobacco smoke potentiates subsequent locomotor responses to nicotine and tobacco smoke but not amphetamine in adult rats. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 100, 109-118.	1.3	15

#	ARTICLE	IF	CITATIONS
109	Development and validation of a LC-MS/MS method based on a new 96-well Hybrid-SPE [®] , [®] c-precipitation technique for quantification of CYP450 substrates/metabolites in rat plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 2371-2381.	1.9	26
110	HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 61-69.	0.6	14
111	The Effect of Critical Illness on Drug Distribution. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2030-2036.	0.9	31
112	Simulation-Based Sodium Thiosulfate Dosing Strategies for the Treatment of Calciphylaxis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1155-1159.	2.2	31
113	Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs. <i>Infectious Disorders - Drug Targets</i> , 2011, 11, 157-166.	0.4	0
114	Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. <i>European Journal of Medical Research</i> , 2010, 15, 533.	0.9	65
115	Tobacco smoke exposure induces nicotine dependence in rats. <i>Psychopharmacology</i> , 2010, 208, 143-158.	1.5	68
116	Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2967-2973.	1.2	18
117	Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 95, 401-409.	1.3	29
118	Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 658-664.	1.9	20
119	Thromboelastographic and pharmacokinetic profiles of micro [®] and macro [®] emulsions of propofol in swine. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 269-277.	1.1	4
120	Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 1107-1122.	1.6	267
121	Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 2521-2528.	1.6	50
122	Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. <i>Therapeutics and Clinical Risk Management</i> , 2010, Volume 6, 485-495.	0.9	7
123	Population Pharmacokinetics and Pharmacodynamics of Inhaled Ciclesonide and Fluticasone Propionate in Patients With Persistent Asthma. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1118-1127.	1.0	16
124	Pharmacometrics as a Discipline Is Entering the [®] Industrialization [®] Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 9S-19S.	1.0	20
125	Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. <i>Annals of the New York Academy of Sciences</i> , 2010, 1207, 134-142.	1.8	4
126	Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 96-97.	1.1	17

#	ARTICLE	IF	CITATIONS
127	Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 431-438.	1.1	57
128	Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. <i>Clinical Pharmacokinetics</i> , 2010, 49, 379-396.	1.6	210
129	Pharmacokinetics I: PK-PD approaches - antibiotic drug development. , 2010, , 143-155.		0
130	In vitro pharmacodynamic models to determine the effect of antibacterial drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 186-201.	1.3	80
131	Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure. <i>Die Pharmazie</i> , 2010, 65, 417-20.	0.3	6
132	Ciclesonide in the Management of Asthma. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2133.	0.1	1
133	Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5039-5045.	1.4	24
134	Pharmacokinetics and Tissue Distribution of Dodeca-2 <i>E</i> ,4 <i>E</i> ,8 <i>E</i> ,10 <i>E</i> / <i>Z</i> -tetraenoic Acid Isobutylamides after Oral Administration in Rats. <i>Planta Medica</i> , 2009, 75, 1306-1313.	0.7	20
135	Toxicological and Pharmacokinetic Evaluation of Concomitant Intake of Grapefruit Juice and Simvastatin in Rats after Repeated Treatment over 28 Days. <i>Planta Medica</i> , 2009, 75, 1196-1202.	0.7	8
136	Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2773-2776.	1.4	36
137	Cortisol suppression as a surrogate marker for inhaled corticosteroid-induced growth retardation in children. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 110-121.	1.9	6
138	Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 970-975.	1.4	10
139	Pharmacodynamic activity of the lantibiotic MU1140. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 70-74.	1.1	62
140	Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 1-7.	1.1	79
141	Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole- <i>Candida</i> interactions. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 240-245.	1.1	8
142	Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 231-235.	1.1	69
143	Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline. <i>Clinical Pharmacokinetics</i> , 2009, 48, 575-584.	1.6	64
144	Influence of the Duffy Antigen on Pharmacokinetics and Pharmacodynamics of Recombinant Monocyte Chemoattractant Protein (MCP-1, CCL-2) <i>in Vivo</i> . <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 615-625.	1.0	22

#	ARTICLE	IF	CITATIONS
145	Bioavailability of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides after oral administration in rats and distribution in various tissues. <i>Planta Medica</i> , 2009, 75, .	0.7	0
146	Proposal for a standardised identification of the mono-exponential terminal phase for orally administered drugs. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 145-157.	1.1	2
147	Pharmacokinetics of Anthocyanins and Antioxidant Effects after the Consumption of Anthocyanin-Rich Açaí Juice and Pulp (<i>Euterpe oleracea</i> Mart.) in Human Healthy Volunteers. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 7796-7802.	2.4	202
148	Assessment of the Impact of Dosing Time on the Pharmacokinetics/Pharmacodynamics of Prednisolone. <i>AAPS Journal</i> , 2008, 10, 331-41.	2.2	21
149	Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1292-1300.	2.7	192
150	Potential of Pharmacokinetic Profiling for Detecting Herbal Interactions with Drugs. <i>Clinical Pharmacokinetics</i> , 2008, 47, 383-397.	1.6	39
151	A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against <i>Candida</i> spp. in vitro. <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 369-374.	1.1	18
152	Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. <i>Neuropharmacology</i> , 2008, 55, 812-818.	2.0	22
153	PK/PD: new insights for antibacterial and antiviral applications. <i>Current Opinion in Pharmacology</i> , 2008, 8, 549-556.	1.7	76
154	Effect of Grapefruit Juice, Naringin, Naringenin, and Bergamottin on the Intestinal Carrier-Mediated Transport of Talinolol in Rats. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 4840-4845.	2.4	48
155	Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3994-4000.	1.4	97
156	The <i>Candida albicans</i> phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence. <i>Microbiology (United Kingdom)</i> , 2008, 154, 3296-3308.	0.7	22
157	Clinical Microdialysis in Skin and Soft Tissues: An Update. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 351-364.	1.0	70
158	Population Pharmacodynamic Model of Bronchodilator Response to Inhaled Albuterol in Children and Adults With Asthma. <i>Chest</i> , 2008, 134, 981-989.	0.4	32
159	Duffy antigen modifies the chemokine response in human endotoxemia. <i>Critical Care Medicine</i> , 2008, 36, 159-165.	0.4	159
160	Pharmacokinetics of Luteolin and Metabolites in Rats. <i>Natural Product Communications</i> , 2008, 3, 1934578X0800301.	0.2	15
161	Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2008, 46, 617-626.	0.3	17
162	Pharmacokinetic profiling of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides in rats using liquid chromatography tandem mass spectrometry. <i>Planta Medica</i> , 2008, 74, .	0.7	0

#	ARTICLE	IF	CITATIONS
163	Tissue concentrations: do we ever learn?. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 235-237.	1.3	333
164	Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curves. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 849-860.	2.5	20
165	Clinical Trials and Dipyridamole Formulation Selection. <i>Cerebrovascular Diseases</i> , 2007, 23, 72-73.	0.8	0
166	Measurement of Voriconazole Activity against <i>Candida albicans</i> , <i>C. glabrata</i> , and <i>C. parapsilosis</i> Isolates Using Time-Kill Methods Validated by High-Performance Liquid Chromatography. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2985-2987.	1.4	14
167	Response to Dr. Blum. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 537-537.	1.0	0
168	Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 237-256.	0.9	45
169	AAPS-FDA workshop white paper: Microdialysis principles, application, and regulatory perspectives report from the Joint AAPS-FDA Workshop, November 4-5, 2005, Nashville, TN. <i>AAPS Journal</i> , 2007, 9, E48-E59.	2.2	16
170	AAPS-FDA Workshop White Paper: Microdialysis Principles, Application, and Regulatory Perspectives. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 589-603.	1.0	76
171	Polymethoxylated Flavones and Other Phenolic Derivates from Citrus in Their Inhibitory Effects on P-Glycoprotein-Mediated Transport of Talinolol in Caco-2 Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2007, 55, 2563-2568.	2.4	32
172	Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 263-270.	1.1	41
173	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisolone. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 27-37.	1.6	59
174	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisone. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1480-1489.	1.6	36
175	Grapefruit Juice – Drug Interactions: Grapefruit Juice and Its Components Inhibit P-Glycoprotein (ABC1) Mediated Transport of Talinolol in Caco-2 Cells. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2808-2817.	1.6	90
176	Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 782-789.	1.0	60
177	A Pharmacokinetic/Pharmacodynamic Approach to Predict Total Prednisolone Concentrations in Human Plasma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 355-372.	0.8	27
178	Exploring mechanisms of grapefruit juice drug interactions and its potential toxicity. <i>Planta Medica</i> , 2007, 73, .	0.7	0
179	The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 149-157.	0.5	19
180	Absorption, Metabolism, and Antioxidant Effects of Pomegranate (<i>Punica granatum</i> L.) Polyphenols after Ingestion of a Standardized Extract in Healthy Human Volunteers. <i>Journal of Agricultural and Food Chemistry</i> , 2006, 54, 8956-8961.	2.4	299

#	ARTICLE	IF	CITATIONS
181	The Influence of Formulation on the Dissolution Profile of Diclofenac Sodium Tablets. Drug Development and Industrial Pharmacy, 2006, 32, 1103-1109.	0.9	9
182	Grapefruit-Drug Interactions: Can Interactions With Drugs Be Avoided?. Journal of Clinical Pharmacology, 2006, 46, 1390-1416.	1.0	100
183	Pharmacokinetic/Pharmacodynamic Profile of Voriconazole. Clinical Pharmacokinetics, 2006, 45, 649-663.	1.6	386
184	The Effect of Protein Binding on Adrenal Suppression Potential of Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology, 2006, 117, S94.	1.5	3
185	Variation of Flavonoids and Furanocoumarins in Grapefruit Juices: A Potential Source of Variability in Grapefruit Juice-Drug Interaction Studies. Journal of Agricultural and Food Chemistry, 2006, 54, 249-255.	2.4	108
186	Extended Stability of Oxytocin in Ringer's Lactate Solution at 4°C and 25°C. Hospital Pharmacy, 2006, 41, 437-441.	0.4	3
187	Clinical microdialysis: Current applications and potential use in drug development. TrAC - Trends in Analytical Chemistry, 2006, 25, 674-680.	5.8	52
188	Pharmacokinetic/Pharmacodynamic Modeling of Total Lymphocytes and Selected Subtypes After Oral Budesonide. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 441-459.	0.8	14
189	Hyperforin in St. John's wort drug interactions. European Journal of Clinical Pharmacology, 2006, 62, 225-233.	0.8	156
190	Microdialysis as a tool in local pharmacodynamics. AAPS Journal, 2006, 8, E222-E235.	2.2	32
191	Variability in Response to Cardiovascular Drugs. Current Clinical Pharmacology, 2006, 1, 35-46.	0.2	17
192	Isolation and HPLC Quantitative Analysis of Antioxidant Flavonoids from Alternanthera tenella Colla. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2006, 61, 19-25.	0.6	38
193	Characterizing the Effects of Caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata Isolates by Simultaneous Time-Kill and Postantifungal-Effect Experiments. Antimicrobial Agents and Chemotherapy, 2006, 50, 2569-2572.	1.4	69
194	Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. Journal of Antimicrobial Chemotherapy, 2006, 58, 632-636.	1.3	53
195	Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. Journal of Antimicrobial Chemotherapy, 2006, 58, 822-829.	1.3	85
196	Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis. Scandinavian Journal of Infectious Diseases, 2006, 38, 904-908.	1.5	11
197	Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal, 2006, 28, 1042-1050.	3.1	212
198	Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. Journal of Antimicrobial Chemotherapy, 2006, 59, 277-284.	1.3	101

#	ARTICLE	IF	CITATIONS
199	Development and Validation of an HPLC Method for Oxytocin in Ringer's Lactate and its Application in Stability Analysis. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2006, 29, 2353-2365.	0.5	8
200	Drug Interactions of Grapefruit and Other Citrus_What Have We Learned?. <i>Drugs and the Pharmaceutical Sciences</i> , 2006, , 147-190.	0.1	0
201	Pharmacokinetics of Botanical Products. <i>Drugs and the Pharmaceutical Sciences</i> , 2006, , 205-244.	0.1	0
202	Evaluation of the effect of grapefruit juice and its components on P-glycoprotein activity. <i>Planta Medica</i> , 2006, 72, .	0.7	0
203	Functional Role of the Chemokine Binding Duffy Antigen Receptor Complex (DARC) in Human Inflammation In Vivo.. <i>Blood</i> , 2006, 108, 20-20.	0.6	0
204	Population Pharmacokinetics of Eniporide and Its Metabolite in Healthy Subjects and Patients With Acute Myocardial Infarction. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 631-639.	1.0	2
205	Application of Two-Point Assay of Digoxin Serum Concentration in Studying Population Pharmacokinetics in Egyptian Pediatric Patients with Heart Failure: Does It Make Sense?. <i>American Journal of Therapeutics</i> , 2005, 12, 320-327.	0.5	2
206	Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 659-665.	1.0	35
207	Pharmacokinetics and Pharmacodynamics of Biotech Drugs. , 2005, , 145-172.		2
208	Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 822-831.	1.0	22
209	Dipyridamole Bioavailability in Subjects With Reduced Gastric Acidity. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 845-850.	1.0	64
210	Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 25, 439-444.	1.9	53
211	Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. <i>Phytomedicine</i> , 2005, 12, 28-38.	2.3	195
212	Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form*. <i>Infection</i> , 2005, 33, 22-28.	2.3	33
213	Tissue Penetration of Cefpodoxime and Cefixime in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 564-569.	1.0	24
214	Pharmacokinetic Studies of Florfenicol in Koi Carp and Threespot Gourami <i>Trichogaster trichopterus</i> after Oral and Intramuscular Treatment. <i>Journal of Aquatic Animal Health</i> , 2005, 17, 129-137.	0.6	68
215	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 601-607.	1.3	448
216	Microdialysis for pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. <i>Current Opinion in Pharmacology</i> , 2005, 5, 495-499.	1.7	75

#	ARTICLE	IF	CITATIONS
217	Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 62-67.	1.1	76
218	Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 120-129.	1.1	51
219	Comparative Pharmacology, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Inhaled Glucocorticosteroids. <i>Immunology and Allergy Clinics of North America</i> , 2005, 25, 469-488.	0.7	94
220	Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 361-373.	2.0	38
221	Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005, 43, 117-122.	0.3	15
222	What is the best marker for inhaled corticosteroid safety?. <i>Allergy and Asthma Proceedings</i> , 2005, 26, 89-93.	1.0	7
223	Pharmacokinetic Herb-Drug Interactions: Are Preventive Screenings Necessary and Appropriate?. <i>Planta Medica</i> , 2004, 70, 784-791.	0.7	65
224	Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1083-1105.	1.0	193
225	How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 356-363.	3.5	98
226	In vitro microdialysis sampling of docetaxel. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 36, 807-813.	1.4	19
227	PK-PD modelling of the effect of cefaclor on four different bacterial strains. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 218-225.	1.1	26
228	Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 494-497.	1.1	16
229	Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1441-1453.	1.4	237
230	Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 369-377.	1.4	262
231	Intranasal Loteprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 510-519.	1.0	8
232	Physiological, Pharmacokinetic, and Pharmacodynamic Changes in Space. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 837-853.	1.0	90
233	Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/ Pharmacodynamic Perspective. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 37-47.	1.0	83
234	Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004, 42, 504-511.	0.3	6

#	ARTICLE	IF	CITATIONS
235	Microdialysis of Triamcinolone Acetonide in Rat Muscle. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 394-397.	1.6	3
236	Antimicrobial tissue concentrations. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 599-613.	1.9	59
237	Inhaled Corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, S1-S40.	1.5	211
238	PK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, S218.	1.5	27
239	Single- and Multiple-Dose Pharmacokinetics of Oral Creatine. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 29-37.	1.0	39
240	Risk-Benefit Value of Inhaled Corticosteroids. <i>Chest</i> , 2003, 123, 430S-431S.	0.4	5
241	Pharmacokinetic/Pharmacodynamic Modeling of Luteinizing Hormone (LH) Suppression and LH Surge Delay by Cetrorelix after Single and Multiple Doses in Healthy Premenopausal Women. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 243-251.	1.0	22
242	Population Kinetics, Efficacy, and Safety of Dichloroacetate for Lactic Acidosis Due to Severe Malaria in Children. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 386-396.	1.0	49
243	A review of the effects of chronic exercise and physical fitness level on resting pharmacokinetics. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 504-516.	0.3	27
244	Systemic Availability and Pharmacokinetics of Thymol in Humans. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 731-737.	1.0	135
245	Interstitial tissue concentrations of cefpodoxime. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 19-22.	1.3	79
246	Comparative Target Site Pharmacokinetics of Immediate- and Modified-Release Formulations of Cefaclor in Humans. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 403-411.	1.0	11
247	Population Pharmacokinetics of Digoxin in Egyptian Pediatric Patients: Impact of One Data Point Utilization. <i>American Journal of Therapeutics</i> , 2002, 9, 492-498.	0.5	12
248	Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 285-290.	1.1	152
249	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. <i>International Journal of Antimicrobial Agents</i> , 2002, 19, 355-358.	1.1	91
250	How Important Are Gender Differences in Pharmacokinetics?. <i>Clinical Pharmacokinetics</i> , 2002, 41, 329-342.	1.6	365
251	Bioavailability and Metabolism of Mometasone Furoate: Pharmacology versus Methodology. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 383-387.	1.0	8
252	Pharmacokinetics and Bioavailability of Herbal Medicinal Products. <i>Phytomedicine</i> , 2002, 9, 1-33.	2.3	253

#	ARTICLE	IF	CITATIONS
253	Pharmacokinetic/Pharmacodynamic Studies in Drug Product Development. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 18-31.	1.6	130
254	Bioavailability and Metabolism of Mometasone Furoate: Pharmacology versus Methodology. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 383-387.	1.0	26
255	Comparative Target Site Pharmacokinetics of Immediate- and Modified-Release Formulations of Cefaclor in Humans. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 403-411.	1.0	10
256	Novel Formulations of Cetrorelix Acetate in Healthy Men: Pharmacodynamic Effects and Noncompartmental Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 995-1001.	1.0	1
257	PK/PD modeling of hormone effects by cetrorelix. <i>BMC News and Views</i> , 2002, 2, .	0.0	0
258	Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 492-499.	1.0	510
259	Evaluation of Pulmonary Absorption Using Pharmacokinetic Methods. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2001, 14, 9-17.	1.2	25
260	Pharmacokinetic/Pharmacodynamic Evaluation of the NHE Inhibitor Eniporide. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 139-148.	1.0	11
261	Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. <i>European Respiratory Journal</i> , 2001, 17, 157-158.	3.1	13
262	Microdialysis. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 211-219.	0.8	106
263	Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. <i>Pharmaceutical Research</i> , 2001, 18, 1310-1314.	1.7	42
264	Population Pharmacokinetics of Intramuscular Quinine in Children with Severe Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1803-1809.	1.4	48
265	Pharmacokinetics and Rectal Bioavailability of Hydrocortisone Acetate after Single and Multiple Administration in Healthy Subjects and Patients. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 536-541.	1.0	13
266	Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium-m-Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP). <i>Journal of Clinical Pharmacology</i> , 2001, 41, 425-434.	1.0	39
267	Single-Dose and Steady-State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus® or Turbohaler® Dry-Powder Inhalers to Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1329-1338.	1.0	34
268	Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 908-917.	1.0	20
269	A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 22, 123-129.	1.4	36
270	Microdialysis in peripheral tissues. <i>Advanced Drug Delivery Reviews</i> , 2000, 45, 189-216.	6.6	144

#	ARTICLE	IF	CITATIONS
271	Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. <i>Pharmaceutical Research</i> , 2000, 17, 328-335.	1.7	8
272	An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. <i>AAPS PharmSci</i> , 2000, 2, 28-37.	1.3	15
273	Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 617-625.	2.3	36
274	A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 733-739.	1.3	67
275	Clinical and pharmacological aspects of accidental triamcinolone acetonide overdose: a case study. <i>Netherlands Journal of Medicine</i> , 2000, 56, 12-16.	0.6	15
276	Pharmacokinetic-Pharmacodynamic Modeling of Testosterone and Luteinizing Hormone Suppression by Cetrorelix in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 266-274.	1.0	35
277	Population pharmacokinetics of digoxin in Korean patients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2000, 38, 291-297.	0.3	9
278	Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. <i>Die Pharmazie</i> , 2000, 55, 223-7.	0.3	4
279	In vitro recovery of triamcinolone acetonide in microdialysis. <i>Die Pharmazie</i> , 2000, 55, 659-62.	0.3	5
280	Pharmacokinetic/pharmacodynamic modeling in drug research and development. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 1399-418.	1.0	122
281	Pharmacokineticâ€¦pharmacodynamic profile of systemic nitric oxideâ€¦synthase inhibition with Lâ€¦NMMA in humans. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 539-544.	1.1	64
282	Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. , 1999, 16, 176-185.		275
283	A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 127-147.	0.6	17
284	Pharmacokinetics and bioavailability of the flavonol quercetin in humans. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1999, 37, 219-33.	0.3	93
285	Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1999, 37, 367-76.	0.3	15
286	Gender differences in pharmacokinetics and pharmacodynamics. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1999, 37, 529-47.	0.3	139
287	Pitfalls in pharmacokinetic multicompartment analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 247-260.	0.6	14
288	Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. <i>European Journal of Clinical Pharmacology</i> , 1998, 53, 459-467.	0.8	65

#	ARTICLE	IF	CITATIONS
289	Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 1998, 21, 444-452.	0.6	63
290	A selective HPLC/RIA for the determination of budesonide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998, 17, 1235-1242.	1.4	12
291	Pharmacokinetic and Pharmacodynamic Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 1998, 35, 49-64.	1.6	243
292	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, S440-S446.	1.5	193
293	Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 769-778.	1.3	30
294	KA 672-HCl, a Neuronal Activator Against Dementia: Tolerability, Safety, and Preliminary Pharmacokinetics after Single and Multiple Oral Doses in Healthy Male and Female Volunteers. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 373-381.	1.0	7
295	Effect of fat distribution on the pharmacokinetics of cortisol in obesity. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1998, 36, 501-5.	0.3	49
296	Dependency of Cortisol Suppression on the Administration Time of Inhaled Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 704-710.	1.0	30
297	Pharmacokinetic/Pharmacodynamic Aspects of Aerosol Therapy using Glucocorticoids as a Model. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 881-892.	1.0	96
298	Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 893-903.	1.0	24
299	Pharmacokinetics of Dichloroacetate in Adult Patients with Lactic Acidosis. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 416-425.	1.0	25
300	Relationship Between Serum and Free Interstitial Concentrations of Cefodizime and Cefpirome in Muscle and Subcutaneous Adipose Tissue of Healthy Volunteers Measured by Microdialysis. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 1108-1113.	1.0	33
301	Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 916-925.	1.0	55
302	Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. <i>Respiratory Medicine</i> , 1997, 91, 22-28.	1.3	110
303	Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 122-128.	1.4	43
304	Comparison of Plasma and Free Tissue Levels of Ceftriaxone in Rats by Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 52-56.	1.6	53
305	Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl- β -cyclodextrin-Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 335-339.	1.6	37
306	Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration. <i>Die Pharmazie</i> , 1997, 52, 529-32.	0.3	8

#	ARTICLE	IF	CITATIONS
307	Pharmacokinetic profile of cefaclor. International Journal of Clinical Pharmacology and Therapeutics, 1997, 35, 374-80.	0.3	14
308	Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. International Journal of Clinical Pharmacology and Therapeutics, 1997, 35, 401-13.	0.3	183
309	Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. International Journal of Clinical Pharmacology and Therapeutics, 1997, 35, 426-33.	0.3	37
310	Clinical PK/PD modelling as a tool in drug development of corticosteroids. International Journal of Clinical Pharmacology and Therapeutics, 1997, 35, 481-8.	0.3	17
311	Mathematical modeling of cortisol circadian rhythm and cortisol suppression. European Journal of Pharmaceutical Sciences, 1996, 4, 341-350.	1.9	45
312	Pharmacodynamic Evaluation of Codeine Using Tooth Pulp Evoked Potentials. Journal of Clinical Pharmacology, 1996, 36, 1126-1131.	1.0	5
313	Pharmacokinetic/Pharmacodynamic Modeling of Cortisol Suppression after Oral Administration of Fluocortolone. Journal of Clinical Pharmacology, 1996, 36, 311-314.	1.0	10
314	AUIC – A General Target for the Optimization of Dosing Regimens of Antibiotics?. Annals of Pharmacotherapy, 1996, 30, 1024-1028.	0.9	28
315	Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharmaceutical Research, 1996, 13, 91-96.	1.7	62
316	Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharmaceutical Research, 1996, 13, 1699-1703.	1.7	32
317	Disposition and Blood Cell Effects of Prednisolone and Methylprednisolone. Clinical Pharmacology and Therapeutics, 1996, 59, 207-207.	2.3	0
318	Determination of Free Extracellular Concentrations of Piperacillin by Microdialysis. Journal of Pharmaceutical Sciences, 1996, 85, 369-372.	1.6	42
319	Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate. Journal of Clinical Pharmacology, 1996, 36, 938-941.	1.0	51
320	Pharmacokinetics and pharmacodynamics of cloprednol. International Journal of Clinical Pharmacology and Therapeutics, 1996, 34, 1-5.	0.3	12
321	Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. International Journal of Clinical Pharmacology and Therapeutics, 1996, 34, 482-8.	0.3	13
322	The Lack of Effect of Aerobic Exercise Training on Propranolol Pharmacokinetics in Young and Elderly Adults. Journal of Clinical Pharmacology, 1995, 35, 885-894.	1.0	23
323	Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats. Pharmaceutical Research, 1995, 12, 134-137.	1.7	29
324	Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharmaceutical Research, 1995, 12, 1096-1100.	1.7	48

#	ARTICLE	IF	CITATIONS
325	Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 302-305.	1.0	100
326	Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 1187-1193.	1.0	51
327	Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. <i>Die Pharmazie</i> , 1995, 50, 610-3.	0.3	19
328	Pharmacodynamic Aspects of Systemic Drug Delivery. <i>Drug Development and Industrial Pharmacy</i> , 1994, 20, 485-502.	0.9	5
329	Pharmacokinetic/Pharmacodynamic Consequences of Space Flight. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 684-691.	1.0	16
330	Response to the Commentary on "Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs". <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1067-1068.	1.6	1
331	Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. <i>Pharmaceutical Research</i> , 1994, 11, 1056-1059.	1.7	15
332	Development of an Oral Drug Formulation for Dichloroacetate and Thiamine. <i>Drug Development and Industrial Pharmacy</i> , 1994, 20, 2425-2437.	0.9	7
333	SC7 receptor-based PK/PD model for corticosteroids. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 92.	1.9	0
334	FC5 PK/PD based characterization of pulmonary targeting. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 102.	1.9	0
335	Systematic delivery of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) via pulmonary instillation in the unanesthetized awake sheep. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 303-306.	1.9	4
336	P140 a selective HPLC/RIA assay for budesonide in biological fluids. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 153.	1.9	0
337	Increased Erythrocyte and Protein Binding of Codeine in Patients with Sickle Cell Disease. <i>Journal of Pharmaceutical Sciences</i> , 1993, 82, 1112-1117.	1.6	11
338	Receptor-Based Pharmacokinetic/Pharmacodynamic Analysis of Corticosteroids. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 115-123.	1.0	120
339	A Reversed Phase Liquid Chromatographic Method for the Determination of Codeine in Biological Fluids with Applications. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1993, 16, 2325-2334.	0.9	6
340	Codeine Disposition in Sickle Cell Patients Compared With Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 811-815.	1.0	6
341	Prednicarbate after Different Forms of Administration. <i>Current Problems in Dermatology</i> , 1993, 21, 147-156.	0.8	0
342	Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. <i>International Journal of Pharmaceutics</i> , 1992, 87, 183-193.	2.6	28

#	ARTICLE	IF	CITATIONS
343	A Selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. <i>Biomedical Chromatography</i> , 1992, 6, 283-286.	0.8	8
344	Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 1210-1215.	1.6	38
345	Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. <i>The International Journal of Clinical Pharmacology, and Toxicology</i> , 1992, 30, 317-24.	0.1	12
346	Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. <i>Clinical Chemistry</i> , 1992, 38, 1491-4.	1.5	28
347	Pharmacokinetics and Oral Bioavailability of Hydrocortisone. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 473-476.	1.0	140
348	Pharmacokinetics of Intravenous Immunoglobulin (Gammagard) in Bone Marrow Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 1151-1154.	1.0	34
349	Sensitive liquid chromatography assay for the determination of amikacin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1991, 9, 251-254.	1.4	31
350	A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1991, 9, 761-767.	1.4	10
351	A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat. <i>Pharmaceutical Research</i> , 1991, 08, 1180-1185.	1.7	10
352	Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. <i>Pharmaceutical Research</i> , 1991, 08, 263-268.	1.7	28
353	Pharmacokinetics and Rectal Bioavailability of Hydrocortisone Acetate. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 835-836.	1.6	17
354	Pharmacokinetics of Ranitidine after Partial Gastrectomy in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 1034-1036.	1.6	3
355	Pharmacokinetics of Rimexolone After Intra-articular Administration. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 476-479.	1.0	21
356	Evaluation of free tissue concentrations of fleroxacin after oral administration. <i>Pharmaceutical Research</i> , 1990, 07, 422-424.	1.7	6
357	A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog. <i>Pharmaceutical Research</i> , 1990, 07, 879-883.	1.7	12
358	Simultaneous determination of propranolol and 4-hydroxypropranolol enantiomers after chiral derivatization using reversed-phase high-performance liquid chromatography. <i>Biomedical Applications</i> , 1990, 527, 351-359.	1.7	15
359	Effects of Truncal Vagotomy and Partial Gastrectomy on the Pharmacokinetics of Propranolol Enantiomers in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 292-294.	1.6	1
360	Extent of Drug Absorption at the Time of Peak Plasma Concentration in an Open One-Compartment Body Model with First-order Absorption. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 462.	1.6	4

#	ARTICLE	IF	CITATIONS
361	Theophylline Absorption and Gastric Emptying after Partial Gastrectomy in Dogs. Journal of Pharmaceutical Sciences, 1990, 79, 968-969.	1.6	4
362	High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic. Journal of Pharmaceutical and Biomedical Analysis, 1990, 8, 67-71.	1.4	18
363	Simultaneous assay of propranolol, diltiazem and metabolites of diltiazem in human plasma by liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 1990, 8, 535-539.	1.4	18
364	The use of 2-hydroxypropyl- β -cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs. International Journal of Pharmaceutics, 1990, 59, 225-230.	2.6	35
365	Systemic absorption of prednicarbate after dermal, oral and pulmonary administration. European Journal of Pharmacology, 1990, 183, 2134.	1.7	0
366	Pharmacokinetic evaluation of β -lactam antibiotics. Journal of Antimicrobial Chemotherapy, 1989, 24, 407-413.	1.3	25
367	Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharmaceutics and Drug Disposition, 1989, 10, 453-464.	1.1	28
368	Pharmacokinetic Aspects of Intra-articular Administration of Glucocorticoids. , 1989, , 474-481.		2
369	Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharmaceutical Research, 1988, 05, 509-513.	1.7	24
370	High-performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration to rats. Pharmaceutical Research, 1988, 05, 172-177.	1.7	35
371	Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β -Cyclodextrins. Journal of Pharmaceutical Sciences, 1988, 77, 981-985.	1.6	65
372	High-performance liquid chromatographic determination of conjugated estrogens in tablets. Journal of Chromatography A, 1988, 450, 414-419.	1.8	13
373	Desensitization of Brain Opiate Receptor Mechanisms by Gonadal Steroid Treatments that Stimulate Luteinizing Hormone Secretion*. Endocrinology, 1988, 122, 2718-2726.	1.4	79
374	Water Soluble Complexes of a Brain-Targeted Drug Delivery System. , 1988, , 399-405.		1
375	Effect of high doses of glucocorticoids on the kinetics of human white blood cells in vivo. Medizinische Klinik, 1988, 83, 159-63.	0.5	1
376	Local Treatment of Respiratory Infections with Antibiotics. Drug Intelligence & Clinical Pharmacy, 1987, 21, 322-329.	0.4	13
377	Pharmacokinetics of dexamethasone and its phosphate ester. Biopharmaceutics and Drug Disposition, 1987, 8, 205-212.	1.1	71
378	HPLC analysis of buprenorphine in plasma and urine using coulometric detection. Journal of Pharmaceutical and Biomedical Analysis, 1987, 5, 303-308.	1.4	11

#	ARTICLE	IF	CITATIONS
379	Disposition of Cefotaxime and its Desacetyl Metabolite in Morbidly Obese Male and Female Subjects. <i>Therapeutic Drug Monitoring</i> , 1986, 8, 189-194.	1.0	37
380	Lack of Clinically Significant In Vitro and In Vivo Interactions between Ranitidine and Sucralfate. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 995-998.	1.6	19
381	Coulometric High-Performance Liquid Chromatographic Analysis of Morphine in Biological Fluids. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 1198-1200.	1.6	24
382	HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1986, 4, 197-206.	1.4	50
383	Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. <i>European Journal of Clinical Pharmacology</i> , 1986, 31, 363-365.	0.8	11
384	Rapid analysis of ranitidine in biological fluids and determination of its erythrocyte partitioning. <i>Biomedical Applications</i> , 1986, 381, 385-391.	1.7	17
385	Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 313-317.	2.3	238
386	Pharmacokinetics of triamcinolone acetonide and its phosphate ester. <i>European Journal of Clinical Pharmacology</i> , 1985, 29, 85-89.	0.8	73
387	Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids. <i>Biomedical Applications</i> , 1985, 341, 131-138.	1.7	30
388	Kinetics of methylprednisolone and its hemisuccinate ester. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 502-507.	2.3	56
389	Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1985, 3, 566-573.	1.4	12
390	Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. <i>Biopharmaceutics and Drug Disposition</i> , 1985, 6, 423-432.	1.1	24
391	Pharmacokinetics of Morphine and its Surrogates VII: High-Performance Liquid Chromatographic Analyses and Pharmacokinetics of Methadone and its Derived Metabolites in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 1203-1214.	1.6	29
392	Antipyrine - new light on an old drug. <i>Pharmaceutical Research</i> , 1984, 01, 225-229.	1.7	2
393	Electrochemical Chromatographic Determinations of Morphine Antagonists in Biological Fluids, with Applications. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 621-624.	1.6	32
394	High-Performance Liquid Chromatographic Assay of Methadone, Phencyclidine, and Metabolites by Postcolumn Ion-Pair Extraction and On-Line Fluorescent Detection of the Counterion with Applications. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 630-635.	1.6	32
395	In vivo-in vitro correlations of salicylate saliva levels and continuous flow cell dissolution rates. <i>International Journal of Pharmaceutics</i> , 1983, 15, 167-175.	2.6	9
396	Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics. <i>Pain</i> , 1982, 12, 329-341.	2.0	30

#	ARTICLE	IF	CITATIONS
397	Cortical-Evoked Potentials and Saliva Levels as Basis for the Comparison of Pure Analgesics to Analgesic Combinations. <i>Pharmacology</i> , 1982, 25, 227-236.	0.9	9
398	Evoked potentials as objective parameters for the analgesic response of weak analgesics. <i>Advances in Neurology</i> , 1982, 32, 375-81.	0.8	2